Stock Taper
EARNINGS CALL ARCHIVE 4 CALLS ON FILE
TARS — Tarsus Pharmaceuticals, Inc.
NASDAQ
FULL STOCK PAGE →

Q3 2025 Earnings Call Summary

NOV 4, 2025
REVENUE
$118.7M +15.6%
NET MARGIN
-10.6% +9.2 PTS
EPS
-$0.30 +37.5%
FREE CASH FLOW
$16.3M +153.8%

No summary has been written for this call yet.